Tesamorelin
Also known as: Egrifta SV, Egrifta WR
GHRH Analog | Visceral Fat Reduction
Overview
Tesamorelin is an FDA-approved synthetic GHRH analog designed for HIV-associated lipodystrophy treatment. It provides selective visceral fat targeting with 15-20% visceral fat reduction in clinical trials while preserving subcutaneous fat.
Key benefits
- FDA-approved formulation
- Selective visceral fat targeting (15-20% reduction)
- Proven clinical efficacy
- Standardized dosing
- 37% liver fat reduction in NAFLD
- Preserved subcutaneous fat
Mechanism of action
Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat.
Molecular data
- Type
- GHRH analog
- Half-life
- 26-38 minutes
Sequence
His-Ala-Asp-Gly-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu
Indications
What the research community uses this compound for, with self-reported effectiveness.
Weight Loss
Metabolic
Body Composition
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 1.4mg | Once daily | — |
| — | 2mg | Once daily | — |
| — | 1-2mg | 5-7x weekly | — |
| — | 2mg | Once daily (12 months) | — |
| — | 1mg | Once daily (20 weeks) | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Injection site reactions (17%)
- Joint pain (13%)
- Water retention
Contraindications
- Active malignancy
- Pituitary disorders
- Pregnancy
Monitoring
- Monitor blood glucose regularly - 3.3-fold increased diabetes risk documented
- IGF-1 levels should be checked monthly - 47% exceed normal range at 26 weeks
References
Primary literature and clinical-trial data informing this entry.